Research + insights
Explore the following resources on medication-assisted treatment, and how it helps improve the lives of patients everywhere. At Ophelia, we’re actively involved in research on this subject, and we’re committed to sharing our knowledge within the industry.
We conducted a study and found that almost 3/4 of Ophelia patients who had in-network insurance stayed in treatment for more than six months. Read article here.
Read more
Remote urine drug testing can be successfully adapted to exclusively virtual telehealth settings. Ophelia provides real-time, face-to-face high-quality care adherent to in-person best practices.
Read more
Telehealth for OUD holds promise to rapidly scale high quality accessible care for individuals affected by the opioid crisis.
Read more
Partner with Ophelia to improve access and drive clinical outcomes
85% of Ophelia patients are engaged in treatment early in care (HEDIS measure: Engagement of Alcohol or Other Drug Treatment measure), more than 5x national average
79% of Ophelia patients are retained in treatment at 180 days (HEDIS measure: Pharmacotherapy for Opioid Use Disorder), more than 2x national average
Ophelia earns a Net Promoter Score (NPS) of 97 among patients, 3x the industry average
